Insider · CIK 0001465914
Aaron I. Davis
Files at MRTX (Mirati Therapeutics, Inc.), RAIN (Rain Oncology Inc.), ITOS (iTeos Therapeutics, Inc.), TNGX (Tango Therapeutics, Inc.), TYRA (Tyra Biosciences, Inc.). First filing -, latest -.
In brief
Aaron I. Davis files SEC Form 4 as director at MRTX (Mirati Therapeutics, Inc.), and also at RAIN (Rain Oncology Inc.), ITOS (iTeos Therapeutics, Inc.), TNGX (Tango Therapeutics, Inc.), TYRA (Tyra Biosciences, Inc.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Aaron I. Davis has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 12 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jun 11, 2024 | ITOS iTeos Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +24,200 | $0.00 | $0 | 24,200 | Jun 13, 2024 |
| May 10, 2024 | ITOS iTeos Therapeutics, Inc. | AGrant or award Common Stock | +1,142,857 | $17.50 | $20M | 2,946,915 | May 14, 2024 |
| Jan 26, 2024 | RAIN Rain Oncology Inc. | UTender of shares Common Stock, par value $0.001 per share | -79,726 | - | - | 0 | Jan 26, 2024 |
| Jan 26, 2024 | RAIN Rain Oncology Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -35,000 | - | - | 0 | Jan 26, 2024 |
| Jan 26, 2024 | RAIN Rain Oncology Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -20,000 | - | - | 0 | Jan 26, 2024 |
| Jan 23, 2024 | MRTX Mirati Therapeutics, Inc. | DDisposition to issuer Common Stock | -43,073 | - | - | 11,252 | Jan 23, 2024 |
| Jan 23, 2024 | MRTX Mirati Therapeutics, Inc. | DDisposition to issuer Common Stock | -4,444 | - | - | 6,808 | Jan 23, 2024 |
| Jan 23, 2024 | MRTX Mirati Therapeutics, Inc. | DDisposition to issuer Common Stock | -6,808 | - | - | 0 | Jan 23, 2024 |
| Jan 23, 2024 | MRTX Mirati Therapeutics, Inc. | DDisposition to issuer Option to Purchase Common Stockderivative | -25,000 | - | - | 0 | Jan 23, 2024 |
| Jan 23, 2024 | MRTX Mirati Therapeutics, Inc. | DDisposition to issuer Option to Purchase Common Stockderivative | -7,520 | - | - | 0 | Jan 23, 2024 |
| Jan 23, 2024 | MRTX Mirati Therapeutics, Inc. | DDisposition to issuer Option to Purchase Common Stockderivative | -11,000 | - | - | 0 | Jan 23, 2024 |
| Dec 29, 2023 | MRTX Mirati Therapeutics, Inc. | AGrant or award Common Stock | +6,808 | $58.75 | $400k | 54,325 | Jan 3, 2024 |
Questions about Aaron I. Davis
Answered from the filings on this page, as of the latest one.
Is Aaron I. Davis buying or selling?
Aaron I. Davis has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Aaron I. Davis's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Aaron I. Davis has 0.
Where does Aaron I. Davis file Form 4?
Aaron I. Davis has filed Form 4 at MRTX (Mirati Therapeutics, Inc.); RAIN (Rain Oncology Inc.); ITOS (iTeos Therapeutics, Inc.); TNGX (Tango Therapeutics, Inc.); TYRA (Tyra Biosciences, Inc.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.